Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) Resistant to Eculizumab
2015-003778-34Phase 2Completed
- Sponsor
- Volution Immuno Pharmaceuticals SA
- Start
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nomacopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Volution Immuno Pharmaceuticals SA. Primary endpoint: Reduction in serum LDH (AUC) from Day 0 to Day 28. Started Dec 2015; status: completed.
02
Drugs
nomacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2015-003778-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003778-34.